G. Schleiermacher

This study identifies three modes of plasticity in neuroblastoma that shape tumour evolution under selective pressures and therapy resistance.

This study evaluates lorlatinib, an ALK inhibitor, in combination with chemotherapy or idasanutlin in preclinical neuroblastoma models, finding synergy in models with high ALK expression.

This study shows that neuroblastoma cells can switch between noradrenergic and mesenchymal identities through epigenetic reprogramming, influenced by both intrinsic factors and the microenvironment.

This study identifies 9 miRNAs associated with metastatic neuroblastoma by analyzing serum miRNome in patient cohorts and xenografted mice.